Analytic validity of cystic fibrosis testing: A preliminary estimate

Glenn E. Palomaki, Linda A. Bradley, C. Sue Richards, James E. Haddow

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Purpose: Derive estimates of analytic sensitivity and specificity of DNA testing for cystic fibrosis in the United States. Methods: Analyze published results of the American College of Medical Genetics (ACMG)/College of American Pathologists (CAP) Molecular Genetics Survey between 1996 and 2001, taking into account difficult, simulated clinical samples included for educational purposes. Results: Analytic sensitivity is 97.9% [95% confidence interval (CI) 96.8-98.7%], and analytic specificity is 99.4% (95% CI 98.7-99.9%) after removing challenges involving dell507 and performing other adjustments. Analytic sensitivity is consistent over the 6 years. Specificity was lower in 1997. Conclusion: These preliminary estimates indicate that analytic validity of cystic fibrosis testing is very good and can likely be improved. To date, fewer than half of the mutations in the panel recommended for preconceptional or prenatal screening have been challenged. The present study highlights the value of performing confirmatory testing when a mutation is identified to reduce false-positive results.

Original languageEnglish (US)
Pages (from-to)15-20
Number of pages6
JournalGenetics in Medicine
Volume5
Issue number1
DOIs
StatePublished - Jan 1 2003

Keywords

  • Analytic sensitivity
  • Analytic specificity
  • Analytic validity
  • Cystic fibrosis
  • Proficiency testing

ASJC Scopus subject areas

  • Genetics(clinical)

Fingerprint Dive into the research topics of 'Analytic validity of cystic fibrosis testing: A preliminary estimate'. Together they form a unique fingerprint.

Cite this